Lowest Price Guaranteed From USD 4,799
The market for technologies and services supporting the long acting drugs market is anticipated to grow at a CAGR of ~13% during the forecast period.
Long acting drug delivery is an innovative drug delivery approach which allows sustained action of a drug for weeks, months or years after single administration and maintains its optimal therapeutic level in the patient’s body. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long acting drug delivery of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. The long acting delivery of drug candidates confers several advantages, such as improved patient compliance, reduced dosage requirement, better medication adherence, decrease in failure risk due to inconsistent usage and more convenience to patients. Of late, the demand for the availability of long acting vaginal rings as multipurpose prevention technologies for women is also surfacing. It is worth mentioning that a suitable combination of dosage form (long acting implants, Long Acting injectables (LAI), vaginal, oral and topical / transdermal dosage forms) and strategy (micro-encapsulation, nanocrystal suspensions, long acting hydrogels and microneedles) enables better biodistribution and exertion of a localized therapeutic action of the drug for an extended duration / extended release. Driven by the ongoing pace of innovation in the formulation of these technologies and the increasing demand for long acting drugs, the long acting drugs technology and services market is anticipated to witness substantial market growth during the forecast period.
The Long Acting Drugs Market: Technologies and Services, 2023-2035: Distribution by Compatible Dosage Form (Long Acting Injectables, Long Acting Implantables, Long Acting Orals, Long Acting Topicals / Transdermals and Other Dosage Forms), Principle (Manipulation of drug release from delivery systems and Manipulation of in vivo clearance), Strategy (Chemical Modification, Micro-encapsulation, Long Acting Hydrogels, Long Acting Implants, Long Acting Microneedles, Multivesicular Liposomes, Nanocrystal Suspensions and Protein Fusion), Type of Molecule Delivered (Small Molecules, Biologics and Other Molecules), Type of Material Used (Polymer based and Non-polymer based), and Key Geographical Regions (North America, Europe, Asia-Pacific and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 market report features an extensive study of the current technologies and service providers landscape, market size and the likely future potential of the long acting drugs technologies and services market, during the given forecast period. It highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. The market report answers the following key questions related to this industry.
Key Benefits of Long Acting Drug Delivery
The standard-of-care treatment options for several diseases, such as schizophrenia, alzheimer’s disease, age-related macular degeneration, HIV prophylaxis, can be bothersome for patients because of regular intake of the prescribed medication. Patient non-compliance can further worsen the disease, where the medication is anticipated to be consumed for several months to years. In order to circumvent the high rate of non-compliance and non-adherence, long acting drug delivery has been considered as a novel pharmacologic strategy. This delivery enables the continuous administration of active pharmaceutical ingredients (biologics, small molecules and peptides) for extended time period (weeks, months or years) after a single dose. In other words, it supports extended releases of the drug API over a specific time period. The technological advancements in the field of long acting drug delivery ascertain therapeutic efficacy, safety and improved drug pharmacokinetic and pharmacodynamic profiles. It is worth highlighting that, in 2021, the United States Food and Drug Administration (USFDA) approved Cabotegravir, the first long acting injectable for the treatment of human immunodeficiency virus (HIV) pre-exposure prophylaxis, with the dosing regimen of once every two months.
Mental health disorders have been the focus for pharmaceutical companies across the world since several years. Several big pharmaceutical companies have invested in R&D for antipsychotic drugs. COVID 19 pandemic further increased the focus on mental health, as the number of cases significantly rose during the pandemic. According to the World Health Organization, 970 million people were living with mental disorder in 2019 and the most common mental health conditions, anxiety and depression saw a 26% and 28% year-on-year rise from 2019-2020. Long acting drugs have allowed to overcome the challenges with drug compliance in this population. Janssen has been at the forefront of long acting antipsychotics development with its Invega portfolio. The company has a monthly injectable Invega Sustenna, three-monthly injectable depot Invega Trinza and the most recently approved twice yearly Invega Hafyera for treatment of schizophrenia. These LAI antipsychotics generated sales of USD 4.1 billion for Janssen in the year 2022.
Currently, more than 100 long acting drug delivery technologies are available / being developed by various industry stakeholders for the treatment of multiple diseases. The design of these technologies is based on either of the two principles, manipulation of drug release from delivery systems or manipulation of in vivo clearance. Amongst the strategies which allow the long-lasting effect, over 30% of the long acting drug delivery technologies are suitable for long acting implants / devices. It is worth mentioning that 70% of the technologies are compatible to formulate Long Acting injectables (depot and long acting injections). It is worth noting that Janssen is one of the key players that successfully launched LAI antipsychotics over the past years. Examples of Long Acting injectables / LAI antipsychotics that have been approved by the USFDA for the treatment schizophrenia include INVEGA HAFYERA™, INVEGA TRINZA™ and INVEGA® SUSTENNA®. , ,
The development and manufacturing of these complex drug products requires great technical skill and scientific expertise. One of the critical factors associated with the development of long acting drugs is the selection of drug therapeutic window and its absorption characteristics. It also encompasses the quantitative determination of drug metabolism and pharmacokinetic (DMPK) properties. In addition, the formulation of these drugs is a complex process, especially if there is inclusion of highly potent molecules. Some of the other challenges include aseptic manufacturing, terminal sterilization, suitable characterization methods, lack of GMP-certified facilities and specialized equipment. Also, scale-up and regulatory filing for a less-defined regulatory pathway often appear as a bottleneck in the clinical and commercial translation of these drugs. In order to mitigate these technical and operational complexities, pharmaceutical companies tend to outsource their operations to the players that offer services for the development and manufacturing of long acting drugs.
Many stakeholders have been making consolidated efforts to forge alliance with other industry / non-industry players for technology licensing, product development and manufacturing purposes. It is worth highlighting that over 90 strategic partnerships have been inked since 2018 in this market. For instance, in 2021, Merck (MSD outside US and Canada) and Gilead Sciences signed a co-development and co-commercialization agreement for Long Acting orals and Long Acting injectable formulations for the treatment of HIV. In the same year, ViiV Healthcare and Halozyme signed an technology licensing agreement wherein ViiV Healthcare gained access to use Halozyme’s ENHANZE® drug delivery technology. This will enable ViiV Healthcare to develop ultra long acting injectables (dosing intervals of three months or longer).
Additionally, in the same time frame, more than 1,200 patents related to long acting drug delivery have been filed / granted, highlighting the continuous pace of innovation in this field. Moreover, the field is evolving continuously, as researchers and industry players aim to enhance the existing technologies and delivery systems. In this context, in the past three years, over 360 long acting drug delivery focused articles have been published. Given the inclination towards cutting-edge long acting technologies, along with innovative approaches to tailor the dosing regimen, we believe that the evolution in technologies and services for long acting drugs market is likely to evolve at a rapid pace, over the forecast period.
Lately, the pharmaceutical industry has witnessed the development of advanced long acting drug delivery technology platforms. This is due to the ability of long acting drugs to obviate the concerns associated with conventional treatment options. Eventually, these patient-centric treatment modalities aid in the reduction of treatment burden and need for surgical intervention. The global long acting drug delivery technologies and services market is projected to grow at a CAGR of ~13% and ~11%, respectively, in the period 2023-2035. Further, in 2035, the long acting drugs delivery technologies market for micro-encapsulation is expected to capture the majority market share. In terms of geography, the long acting drugs delivery services market in North America and Europe is anticipated to grow at a relatively faster CAGR during the forecast period.
Examples of key companies engaged in providing technologies for long acting drugs market (which have also been captured in this market report) include 3-D Matrix, Alnylam Pharmaceuticals, Amorphex Therapeutics, Bostal Drug Delivery, Cipla, Delpor, Heron Therapeutics and Nanexa.
In addition, examples of key companies offering long acting drugs delivery services (which have also been captured in this market report) include Ascendia Pharmaceuticals, Caplin Steriles, Evonik, Indoco Remedies, Phosphorex and TTY Biopharm. This market report includes an easily searchable excel database of all the companies providing technologies and services for development of Long Acting drugs worldwide.
Several recent developments have taken place in the field of long acting drugs. We’ve outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis.
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different attrributes / segments as defined in the below table:
|Forecast Period||2023 – 2035|
|CAGR||~13% (for technologies)
~11% (for services)
|Principle||Manipulation of drug release from delivery systems, Manipulation of in vivo clearance|
|Strategy||Chemical Modification, Micro-encapsulation, Long Acting Hydrogels, Long Acting Implants, Long Acting Microneedles, Multivesicular Liposomes, Nanocrystal Suspensions, Protein Fusion|
|Compatible Dosage Form||Long Acting Injectables, Long Acting Implantables, Long Acting Oral, Topical / Transdermal, Vaginal, Other Dosage Forms|
|Type of Molecule Delivered||Small Molecules, Biologics, Other Molecules|
|Type of Material Used||Polymer based, Non-polymer based|
|Key Geographical Regions||North America, Europe, Asia-Pacific, Middle East and North Africa|
|Key Companies Profiled||Adare Pharma Solutions, AMW, Bostal Drug Delivery, Creative Biolabs, ForDoz Pharma, Innocore Pharmaceuticals, Integral BioSystems, LATITUDE Pharmaceuticals, Navin Saxena Research and Technology Centre (NSRT), Samyang Biopharm|
|Customization Scope||15% Free Customization Option|
|PowerPoint Presentation (Complimentary)||Available|
|Excel Data Packs (Complimentary)||Technology Landscape Analysis, Service Providers Landscape Analysis, Technology Competitiveness Analysis, Company Competitiveness Analysis, Partnership and Collaboration Analysis, Publication Analysis, Patent Analysis, Grant Analysis, Market Forecast and Opportunity Analysis|
The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report features:
One of the key objectives of the market report was to evaluate the current opportunity and future potential associated with technologies and services for long acting drugs market, over the forecast period. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the forecast period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as principle (manipulation of drug release from delivery systems and manipulation of in vivo clearance), strategy (chemical modification, micro-encapsulation, long acting hydrogels, long acting implants, Long Acting microneedles, multivesicular liposomes, nanocrystal suspensions and protein fusion), compatible dosage form (Long Acting injectables, Long Acting implantables, Long Acting orals, topical / transdermal, vaginal and other dosage forms), type of molecule delivered (small molecules, biologics and other molecules), type of material used (polymer based and non-polymer based) and key geographical regions (North America, Europe, Asia-Pacific and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in this field. The report features detailed transcript of interview held with the industry stakeholders.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.